All News

steroids.prednisone.pills_.jpg

Vamorolone: a New Steroid on the Horizon?

Jack Cush, MD

Vamorolone is a potentially new alternative to traditional glucocorticoids for use in inflammatory diseases.

Read Article
infx.pneumonia.jpg

Steroids, Prophylaxis and Pneumocystis Pneumonia

Jack Cush, MD

A case-control study has shown that glucocorticoids and tapering glucocorticoids are risk factors for the development of Pneumocystis jirovecii pneumonia (PJP).

Read Article
GCA,woman

Upadacitinib for Giant-Cell Arteritis - A Phase 3 Trial

Jack Cush, MD

The NEJM has published a randomized controlled trial in giant-cell arteritis (GCA) patients, demonstrating significant efficacy and safety of upadacitinib (UPA), given as 15 mg daily, as compared to placebo. 
 

Read Article
hip.THR_.jpg

Joint Implant Metals May Be Leaking

MedPage Today

Patients with metal-containing joint replacements had significantly higher concentrations of cobalt in their cerebrospinal fluid (CSF) relative to patients without arthroplasties, researchers reported.

Read Article
Stillsnow, Stills, podcast

1st Line Biologics vs csDMARDs in Adult Still's Disease

Jack Cush, MD

A German multicentre, retrospective study assessed the first-line efficacy of biologics and conventional synthetic DMARD therapy in patients with adult-onset Still's disease and found biologic agents were significantly better with sustained, event-free remissions and fewer complications.

Read Article
LBP_0.jpg

Consensus Against Interventional Injections for Chronic Spinal Pain

Jack Cush, MD

BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or inflammatory arthropathy.

Read Article
RheumNow Podcast square

Cancer Survival with TNF Inhibitors (3.28.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
falls.jpg (keep)

Cardiac-MSK Patients at Highest Risk for Falls and Death

EurekAlert!

A new study by researchers at Peking University and the Chinese PLA General Hospital has found that multimorbidity—living with multiple chronic diseases—is closely associated with worsening fall conditions and mortality among middle-aged and older adults in China.

Read Article
JAK Janus

Treating chronic inflammatory diseases with JAK inhibitors

Science Daily

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

Read Article
South Korean nationwide cohort study of 888,909 newly diagnosed #OA pts compared NSAID safety. Nephrotoxicity varied: lowest w/ meloxicam (aHR=1.22 [0.68–2.19]), higher w/ loxoprofen (aHR=3.9 [1.56–10.00]), celecoxib (aHR=2.4 [1.68–3.53]), naproxen (aHR=4.7 [2.16–10.24]) https://t.co/wfWIdoRQGO
Dr. John Cush RheumNow ( View Tweet)
To promote broader avail. of biosimilars in EU, EMA has proposed a new path for new biosimilars, omitting comparative clinical trial data, as long as biosimilar shows structural & functional comparability, w/ pharmacokinetic & interaction data (relative to reference product) https://t.co/24aTCuDwdO
Dr. John Cush RheumNow ( View Tweet)
Joint Implant Metals May Be Leaking Patients with metal-containing joint replacements had significantly higher concentrations of cobalt in their cerebrospinal fluid (CSF) relative to patients without arthroplasties, researchers reported. https://t.co/ubDhWqtTSL https://t.co/GjMnog8mcJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Vamorolone, a promising alternative to traditional glucocorticoids for inflammatory diseases. ◦ #Vamorolone is a dissociated steroid compound with reduced side effects. ◦ Unlike conventional #glucocorticoids, vamorolone lacks the hydroxyl or ketone groups and is resistant to https://t.co/yvDWqcbXbn

Links:

Alberto Giraldo alb_giraldo ( View Tweet)
Cancer Survival with TNF Inhibitors Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv https://t.co/MKJKAi0BPV

Links:

Dr. John Cush RheumNow ( View Tweet)

Obstacles to the current use of DMARDs from patients, discussed during regular appointments, were mainly associated with adverse effects and worries about effectiveness and long-term usage. Ongoing attention to these patients' concerns is crucial for improving treatment https://t.co/hWYGiPIsBb
Dr. John Cush RheumNow ( View Tweet)
Barriers to current DMARD use from pts, discussed during routine visits were primarily related to side effects and concerns about the efficacy and long-term use. Continuous attention to these patients’ concerns are key to better treatment adherence https://t.co/J0kPR2CQyH https://t.co/D84t4dPdLO

Links:

Dr. John Cush RheumNow ( View Tweet)
Adrenal Dysfunction after Steroids in PMR and GCA Patients JAMA has published a study of PMR and GCA patients who stopped glucocorticoid (GC) therapy and noted a low (1.2%) risk of GC-induced adrenal insufficiency after planned cessation. https://t.co/zQSa8ex9na https://t.co/gkKxHFPuNe

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase 3 RCT shows that SC Abatacept was not effective in treating Active Idiopathic Inflammatory Myopathy: 148 (double-blind) & 133 (OL) pts Rx for 24wks with similar improvement 56% ABA vs 42.5% PBO (P = 0.083); NS at 52 wks & w/ dermatomyositis. https://t.co/InlHJSmiKn https://t.co/mtFQWp3vlb

Links:

Dr. John Cush RheumNow ( View Tweet)
Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) based on reference products: Prolia (denosumab) and Xgeva (denosumab) respectively. US launch mid-2025 https://t.co/0i5ZMJSxnp https://t.co/zeQ7QhmA0n

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/VkPL7thzo8 https://t.co/h85iF6tIVk

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×